“ I’ m quite encouraged about the momentum in drug development led by MJFF in partnership with the PD community.”
2021 in Review and What’ s Next
13
Positive Phase III Results
MJFF partner Amneal Pharmaceuticals in New Jersey announced positive Phase III results from their carbidopa / levodopa extended-release compound. The extended-release capsules worked better than immediate-release tablets at reducing“ off” time in people with advanced Parkinson’ s and motor fluctuations. They plan on submitting a New Drug Application to the FDA mid-2022.
New App Makes DBS Adjustments More Accessible
Abbott, maker of Infinity deep brain stimulation( DBS) devices, now allows patients to receive stimulation adjustments remotely through an app. This technology can help if you live far from your doctor or have issues with travel. MJFF successfully advocated for insurance coverage of this service during the COVID-19 pandemic.
“ I’ m quite encouraged about the momentum in drug development led by MJFF in partnership with the PD community.”
— Jeff Keefer, Vice Chairman, MJFF Board of Directors